Group 1 - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment [1] - The article suggests that investors consider buying JAZZ stock based on analysts' recommendations [1]

Core Insights - Jazz Pharmaceuticals has achieved a significant milestone by generating over $1 billion in annual product sales from its cannabis-derived therapy, Epidiolex, marking its entry into blockbuster territory [2][10] Group 1: Epidiolex Performance - Epidiolex generated $1.1 billion in product sales in 2025, accounting for approximately 25% of Jazz's total revenues, with a year-over-year growth of 9% driven by strong prescription demand [4][10] - The growth of Epidiolex is no longer limited to pediatric patients, with the company identifying adult patients, especially in long-term care settings, as a key growth opportunity [5] - Jazz has resolved nearly all outstanding ANDA litigations related to Epidiolex, extending patent protection into the late 2030s, which enhances revenue visibility and reduces the threat from generic competition [6][10] Group 2: Diversified Portfolio - Jazz Pharmaceuticals has a diversified biopharma portfolio that includes products in neuroscience and oncology, in addition to its cannabis-derived therapies [7] - The oxybate franchise, particularly Xywav, has become a significant growth driver, providing treatment for narcolepsy without the sodium-related warnings associated with previous formulations [8] - Oncology sales now account for over 26% of Jazz's total revenues, supported by new product launches and increasing market share [9] Group 3: Pipeline and Market Position - Despite commercial successes, Jazz has faced setbacks in its pipeline, including the discontinuation of suvecaltamide and disappointing results from a mid-stage study on JPZ150 for PTSD [12][13] - Jazz's stock has risen 11% year-to-date, outperforming the industry average of 8%, although earnings estimates present a mixed outlook for 2026 and 2027 [14][16] - Compared to pure-play cannabis companies, Jazz offers a more balanced risk profile, with recurring cash flows from its neuroscience and oncology products, while Epidiolex provides exposure to the medical cannabis market projected to exceed $130 billion by 2032 [18]

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely.Our biotech Top Picks increased 137.6% last year with a 37.2% CAGR since 2017, along with a mid-20s CAGR for our core portfolio LTGP (CAGR performance as of Feb 20, 2026).To receive e-mail notifications for my public articles and blogs, ...

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely.Our biotech Top Picks increased 137.6% last year with a 37.2% CAGR since 2017, along with a mid-20s CAGR for our core portfolio LTGP (CAGR performance as of Feb 20, 2026).To receive e-mail notifications for my public articles and blogs, ...

Key Takeaways JAZZ posted Q4 EPS of $6.64 and revenues of $1.2B, topping estimates; shares rose 5% after hours.Jazz's neuroscience sales rose 8%, led by 16% growth in Xywav and 12% gain in oxybate franchise.JAZZ guides 2026 revenue of $4.25B-$4.50B, expecting double-digit epilepsy and oncology growth.Jazz Pharmaceuticals (JAZZ) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.64 per share, which beat the Zacks Consensus Estimate of $6.62. Earnings rose 2% year over year.Total revenues ro ...

For the quarter ended December 2025, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2 billion, up 10.1% over the same period last year. EPS came in at $6.64, compared to $6.60 in the year-ago quarter.The reported revenue represents a surprise of +1.56% over the Zacks Consensus Estimate of $1.18 billion. With the consensus EPS estimate being $6.62, the EPS surprise was +0.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.64 per share, beating the Zacks Consensus Estimate of $6.62 per share. This compares to earnings of $6.6 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.27%. A quarter ago, it was expected that this drugmaker would post earnings of $5.74 per share when it actually produced earnings of $8.13, delivering a surprise of +41.64%.Over the last four quarters, the c ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJohn Bluth - Head of Investor RelationsMichael Riad - VPMohit Bansal - Managing DirectorPhil Johnson - EVP and CFORenee Gala - President and CEORob Iannone - EVP of Research and DevelopmentSam Pearce - Chief Commercial OfficerNone - ShareholderConference Call ParticipantsAmi Fadia - Senior AnalystBrian Skorney - Senior Research AnalystDavid Amsellem - Managing Director and Senior Research AnalystDavi ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJohn Bluth - Head of Investor RelationsMichael Riad - VPMohit Bansal - Managing DirectorPhil Johnson - EVP and CFORenee Gala - President and CEORob Iannone - EVP of Research and DevelopmentSam Pearce - Chief Commercial OfficerNone - ShareholderConference Call ParticipantsAmi Fadia - Senior AnalystBrian Skorney - Senior Research AnalystDavid Amsellem - Managing Director and Senior Research AnalystDavi ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker12Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals Fourth Quarter 2025 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is ...